Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib vs Imatinib + Peg-Interferon in Ph+ CML
NCT00297570Phase 3Unknown
- Sponsor
- Sheba Medical Center
- Start
- Feb 2006
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pegylated interferon alpha in Chronic Myeloid Leukemia (CML), sponsored by Sheba Medical Center. Primary endpoint: Rate of achievement of molecular remission. Status: unknown.
02
Drugs
pegylated interferon alpha
03
Conditions
Chronic Myeloid Leukemia (CML)
Beyond the preview
Go deeper on NCT00297570.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00297570.